Immutep (ASX:IMM) – innovative cancer therapies
30 Mar 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.